AMST
A tiny revenue line, a very loud stock move
Amesite did what small-cap stocks do best: it turned a modest operating update into a fireworks show. The company reported Q3 revenue of just $83,332, up from $30,690 a year ago, while its loss narrowed slightly to 15 cents per share from 16 cents.
That’s not exactly "we’re printing cash" territory. But when you’re a company like Amesite, investors often care more about direction than size. And the direction here was up.
The real sugar rush: a new customer
The bigger headline was Amesite’s announcement that it landed a new enterprise customer for NurseMagic, its AI-native documentation platform. The deployment covers about 2,700 patients, making it the company’s largest rollout so far.
That matters because it gives the business a fresh data point that says: this isn’t just a demo reel and a hopeful pitch deck. The platform is getting used in the real world, across workflows tied to electronic medical records and visit verification.
Why investors cared so much
Amesite says the system could cut administrative work that can eat up as much as 16 hours per caregiver per week. If that kind of efficiency claim holds up, it’s the sort of value proposition healthcare buyers actually notice — especially in non-acute care, where staffing pain is basically a permanent feature.
The company also pointed to roughly 4,200 website visits per day and rising inbound interest, which is the startup equivalent of saying "people are looking at the menu." Still, one customer does not make a monster business. But for a stock that lives on momentum, it’s enough to get traders leaning forward.
Big picture
Amesite is still tiny, still lossy, and still very much in prove-it mode. But today’s move suggests investors are willing to pay up for any sign that NurseMagic can turn interest into actual deployments. In microcap land, that’s often all it takes to send the chart vertical.